DADA

DADA is diisopropylamine dichloroacetate, a non-peptide discussed for energy, endurance and ME/CFS metabolism. Promotional benefits contrast with reports of faintness, weakness and painful skin sensitivity; independent benefit evidence is sparse.

What DADA is

• DADA and DCA are related, but separate identities. DADA is the diisopropylamine salt of dichloroacetic acid. DCA discussion often concerns another form, such as sodium dichloroacetate; an account labeled DCA cannot automatically become a DADA report, and equal milligrams do not establish equal exposure. Animal context Community
• The attraction is a proposed change in fuel use. PDK enzymes act as a brake on PDH, which helps move fuel from sugar breakdown into mitochondrial metabolism. DADA inhibited PDK in laboratory work and improved several outcomes in influenza-infected mice; that rationale does not demonstrate more stamina in people. Animal context
• “Vitamin B15” is an unreliable shortcut. Older discussion links DADA with pangamic acid, but that label has covered uncertain preparations. FDA guidance does not establish it as a vitamin with a demonstrated nutritional need; a B15 label alone does not identify a DADA product. Community Official context

Benefits people discuss

• Endurance and energy claims are commercially influenced. Biohackingu claims better energy and endurance in a guide carrying a vendor link and discount code. No measured performance accompanies the claims. Personal report
• ME/CFS interest begins with a question. Phoenix Rising members discussed whether changing PDK activity could help symptoms. The personal outcomes quoted in that conversation concern DCA, including benefit, stomach trouble, mood concerns with co-use, and no benefit; they do not establish DADA effects. Community

Doses people discuss

• Injected: 100–300 mg/day in one promotional guide. The author reports 100 mg before training plus 100 mg before bed: 200 mg/day. Precise injection route is unspecified; no safe or common range follows. Personal report
• Oral: 300 mg/day in the same author’s later account. The March 2025 author found this similar to 200 mg injected, perhaps slightly weaker. Subjective similarity establishes neither bioavailability nor route equivalence. Personal report
• Subcutaneous: 50–200 mg per use in a negative account. A different commenter reports no effect below 50 mg and weakness at higher amounts. These intermittent pre-cardio amounts are per use, not daily totals. Personal report

Half-life

• Human DADA half-life remains unknown here. Neither dosing habits nor subjective comparisons establish how quickly DADA leaves the body. Personal report Personal report Personal report

When effects are noticed

• Positive onset is not reliably timed. The oral-switch author describes pre-workout use and build-up with repetition, without timing the first benefit. Personal report
• Unwanted effects were rapid in one account. The commenter felt too weak and close to passing out to reach the gym about 15 minutes after injection. Low blood pressure was self-described, without measurements. Personal report

How long effects last

• A dependable benefit window is unknown. The positive account supplies no hours of benefit or measured persistence after stopping. Personal report
• Weakness reportedly lasted only on injection days. In an earlier reply, the same author limits weakness and self-described low blood pressure to the day of injection; this is felt duration, not clearance. Personal report
• Pain from ordinary touch reportedly resolved after several weeks. A later reply describes complete resolution after a few weeks taking ARA-290. That timing does not establish what caused recovery or prove ARA-290 treated it. Personal report

Periods of use and breaks

• A few weeks on and a few weeks off is one author’s suggestion. The guide’s reason is injection burden, not evidence of a safe cycle or adequate washout. Personal report
• Initial stopping was followed by later reuse. The author first described roughly 50–100 mg every 2–3 days for about 1.5 weeks before skin pain and discarding a vial. Later they reported using remaining DADA at night with no positive effects; restart amount, frequency and the product sequence are unclear. Personal report Personal report

What deserves caution

• The same author later suspected tirzepatide co-use. They suspected the combination in the original episode and described recurrent localized sensitivity lasting several days when DADA was used within about a day of tirzepatide, reportedly 7–10 mg or more. These unverified recollections establish neither an interaction nor a safe spacing rule. Personal report
• A separate commenter reports urinary difficulty. Evilrider2024 mentions trouble urinating without identifying route or amount. Like the detailed adverse account above, this establishes neither frequency nor causality. Personal report
• DCA’s nerve-toxicity evidence matters without becoming DADA data. A randomized DCA trial in people with MELAS, a mitochondrial disorder, ended early because of peripheral nerve toxicity and found no demonstrated benefit under its conditions. It is a reason to question blanket reassurance about this chemical family, not a measured DADA risk rate. Official context
• “Cardarine without cancer risk” is not established. One Reddit question repeats that comparison without evidence. An indexed abstract excerpt from a 1982 laboratory report describes DADA and diisopropylamine mutagenicity in an Ames bacterial assay; the full paper was not accessible here, and this is neither proof of human cancer nor a basis for calling DADA cancer-free. Community Official context
• Product and route uncertainty remain. Neither changing routes nor a vitamin label verifies contents or safety. Personal report Personal report Official context

Community experience and comparisons

• Oral convenience changed one promoter’s preference. The follow-up favors oral use. These posts are one person’s changing account, not independent successes. Personal report Personal report
• Sleep and stack claims need their co-use attached. The claimed sleep improvement involved melatonin. Suggested endurance combinations establish neither DADA’s isolated effect nor safe synergy. Personal report
• Cardarine is the marketing comparison, not another name for DADA. A later question asks about DADA after rejecting Cardarine and also raises meldonium co-use. A visible reply reports no endurance improvement on mildronate with anabolic steroids; it never confirms DADA use and therefore is not a DADA nonresponse. Community
• The ME/CFS thread also questions whether the right material is being discussed. A member’s B15 purchase prompted questions about contents. Those unresolved preparations cannot establish DADA effects. Community

What the research can explain

• The influenza paper supplies a mechanism, not a human endurance result. Yamane and colleagues compared DADA and DCA enzyme inhibition and studied oral DADA in infected mice. Laboratory preference for PDK4 over PDK2 does not prove selective effects, effectiveness or safety in people using it for training or ME/CFS. Animal context
• Animal detection work does not fill the human half-life gap. An older horse-study abstract describes methods that did not detect DADA or free diisopropylamine in blood. Failure to detect a substance with those methods is not a human clearance measurement. Animal context